Preclinical and Toxicology Advisor

Preclinical and Toxicology Advisor

Jaswant S. Gidda, Ph. D. has extensive drug discovery and development experience in big pharma (Eli Lilly & Co) and as an entrepreneur in biotechnology industry. He is currently President, Chief Executive Officer and Director of Anagin, Inc and previously was part of the original team of Marcadia Biotech and Calibrium LLC and served as Vice President of Research and Development.  Jaswant is co-discoverer and developer of two market drugs (Axid® and Enterg ® ) and has led more than 20 program or project teams through Phase 1 and II. Jas has sixteen US issued patents (use and composition of matter)

Jaswant received his Master of Honors and Ph. D. from Panjab University, India and his post- doctoral training in neuropharmacology at University of Texas Southwestern Medical School.  Over the years he has acquired experience in Neuroscience, endocrinology and Gastroenterology. Jas taught at University of Texas and Harvard medical school and has numerous publications in prestigious journals such as PNAS, J. Pharmacol. Exp. Ther., Journal of neurophysiology, American Journal of physiology, Gastroenterology and Nature Chemical Biology

Back to Team
Preclinical and Toxicology Advisor